

ADDITIONAL
VENTURES

IMPACT REPORT 2025

Initiatives and Investments in Single Ventricle Research
January – December 2025



As patients and families, we bring lived experience that helps ensure single ventricle research stays grounded in real needs and real outcomes. By partnering as collaborators — not afterthoughts — we help shape research priorities, strengthen innovation, and accelerate progress that improves care across the lifespan.

– Additional Ventures Patient and Family Advisory Board



From Our Founder

Over half a decade ago, Additional Ventures launched with a clear conviction: progress toward curing single ventricle heart disease was possible, but only if the research field was resourced differently.

At the time, promising ideas and passionate scientists existed, but the systems needed to accelerate discovery, collaboration, and long-term impact did not.

Thus far, we've focused on changing those conditions by investing deeply in discovery, innovation, and community. Prioritizing coordination, collaboration, and community proved that while incremental advances were welcome, larger scale, long-term outcomes were within reach. Our all-in approach resulted in the field we see today — one that is more connected, more capable, and better positioned to translate insight into impact than it was just five years ago.

Single ventricle research now rests on a solid bedrock of infrastructure, connectivity, and readiness — enabling a successfully multidisciplinary effort to fundamentally revolutionize single ventricle treatment and care.

The stories that follow capture a field actively expanding to include new levels of scientific exploration, and a community equipped to unlock the next phase of innovation and progress toward cures. What this community has accomplished in five years now carries us into the uncharted territory ahead — and we remain committed to advancing with rigor, strategic direction, and shared purpose.


Sincerely,



Erin Hoffmann
Executive Chairman and Founder

Our 2025 Programs

Collectively, Additional Ventures' initiatives comprise essential components of our strategy for curing single ventricle.




Cures Collaborative

A multidisciplinary **9-person team** working together to develop a tissue engineered solution that can improve cardiac function and reduce poor outcomes associated with single ventricle heart disease.



Single Ventricle SOURCE

A first-of-its-kind genomic sequencing study aimed at uncovering the causes of single ventricle heart disease, comorbidities, and sequelae. More than **800 patients** and families have enrolled in SOURCE.



Expansion Award

A one-time **\$50,000** award that enables teams to rapidly develop, test, and implement novel, high-risk ideas in the single ventricle space.




Single Ventricle Research Fund

Our flagship research award program that provides foundational support for early-career and independent investigators. To date, we have invested nearly **\$49M** in single ventricle research through SVRF.




Collaborative Sciences Award

A high-touch, targeted grant program — funded jointly with the American Heart Association — that allows researchers to make significant scientific advancements in the field of single ventricle sequelae. To date, 5 teams have been awarded, with a total investment of **\$13M**.



Translational Accelerator

A new, first-of-its-kind accelerator that bridges the “valley of death” in single ventricle research by removing early-stage roadblocks, starting with the **Device Innovation Award**.



Catalyst to Independence

An annual research award program supporting senior-level postdocs through transition to early career faculty with **\$1.2M** over a period of up to 6 years.



Single Ventricle Investigator Meeting (SVIM)

Returning in **October 2026**, SVIM is the premier, multidisciplinary convening focused exclusively on accelerating progress in single ventricle heart disease.



For-Profit Investments

Strategic commercial investments in product-oriented organizations with complementary capabilities, made to advance innovation through multiple pipelines and help **life-changing products** reach patients.

Our Support for Research Across the Translational Pipeline

In 2025, Additional Ventures continued to support single ventricle research across the full translational pathway — supporting early discovery, proof-of-concept development, and clinical evaluation. By building momentum at multiple points concurrently, we aim to shorten the distance between insight and impact.



Where are we now?

Our funded research pipeline reflects the expanding frontier of what single ventricle research can now deliver — from understanding and preserving lymphatic function to modeling Fontan-associated liver disease, from engineering new tools and tissues to testing therapies and noninvasive interventions in patients. Below are just six examples of Additional Ventures-funded research across the translational pipeline.

Discovery

1. Preserving Lymphatic Function

Dr. Sanjeev Datar and Dr. Johnny Hwang at the University of California San Francisco are working to identify biomarkers and develop potential treatment strategies for the pulmonary lymphatic complications associated with single ventricle heart disease.

2. Modeling Fontan-Associated Liver Disease

At the University of Pittsburgh, Dr. Daniel Shiwarski is using his model to reveal how FALD develops and worsens over time. In parallel, Dr. Vahid Serpooshan at the University of Texas Health Science Center at Houston is leveraging his model to identify novel biomarkers and test potential treatments.

Proof-of-Concept

3. Detecting Blood Flow Abnormalities

Dr. Ellis Meng at the University of Southern California is developing a sensor-shunt system capable of automatically detecting blood flow complications in shunted patients.

4. Tissue Engineering

Dr. Milica Radisic at the University of Toronto is developing methods to bioprint a functional ventricle using human cells. Dr. Yibing Qyang at Yale University is developing methods to restore function to patient-derived heart cells for use in tissue engineering.

Preclinical & Clinical Trials

5. Heart Failure Therapeutics

Dr. Shelley Miyamoto at the University of Colorado is leading a clinical trial to evaluate whether SGLT2 inhibitors can improve outcomes and quality of life in Fontan patients.

6. Noninvasive Interventions

Dr. Andrew Spearman at the Medical College of Wisconsin is investigating the therapeutic potential of anti-inflammatory steroids to treat and prevent pulmonary vascular malformations associated with the Glenn circulation.

The SOURCE Study: Building the Largest Genomic Single Ventricle Database

In its first full year of recruitment, SOURCE advanced from an ambitious concept to a rapidly growing dataset designed to serve as essential scientific infrastructure for single ventricle research. By pairing whole genome sequencing with validated clinical data and by prioritizing scale, accessibility, and collaboration, SOURCE is rapidly becoming a cornerstone for discovery in single ventricle heart disease. Three early milestones now illustrate how quickly that foundation is taking shape.



A Rapidly Growing, Deeply Engaged Community

800+ participants enrolled to date — including **425+** patients and **375+** family members — forming one of the largest and most deeply engaged single ventricle research cohorts ever assembled

Unprecedented Diagnostic Breadth

Representation across **10+** distinct single ventricle subtypes, enabling cross-subtype analyses and comparative insights not previously possible at this scale

First Whole Genome Data Delivered

Whole genome sequencing completed for **500+** participants', with early findings already shaping new and more precise research questions

These achievements, along with the launch of our first in-clinic recruitment site at Boston Children's Hospital, signal strong momentum and widespread enthusiasm from patients, families, and clinical partners. They also mark SOURCE's rapid evolution into the most comprehensive genomic effort ever undertaken in single ventricle heart disease.

Participants Enrolled to Date



- Patients
- Family



What's Ahead: reSOURCE for Researchers

In the coming year, reSOURCE, the largest single ventricle **genomic and clinical dataset**, will be released to the researcher community. This shared resource will enable studies spanning genetics, risk stratification, comorbidities, and disease modifiers, accelerating discovery across the field.

As SOURCE continues to grow and reSOURCE comes online, the single ventricle community gains something it has never had before: the scale, depth, and accessibility of data needed to unlock the causes of single ventricle disease and comorbidities, and accelerate breakthroughs that meaningfully transform patient outcomes. By pairing scale with accessibility, SOURCE is not only accelerating discovery, it is reshaping the kinds of questions the field can ask.

10+ Distinct Single Ventricle Subtypes Represented

1. Atrioventricular canal defect
2. Double Inlet Left Ventricle (DILV)
3. Double Inlet Right Ventricle (DIRV)
4. Double Outlet Right Ventricle (DORV)
5. Ebsteins
6. Hypoplastic Left Heart Syndrome (HLHS) or small left-sided structures
7. Mitral atresia (including mitral atresia with DORV)
8. Pulmonary atresia with intact ventricular septum (PA-IVS)
9. Tricuspid atresia (TA)
10. Other hypoplastic right ventricle or small right-sided structures

Investigators Strengthening the Core of Single Ventricle Science

Through our Foundational Science programs — the Single Ventricle Research Fund (SVRF), the Collaborative Sciences Award (CSA), the Expansion Award, and the Catalyst to Independence Award — Additional Ventures has helped build a stronger, more connected single ventricle research ecosystem. Together, these programs have expanded the field’s capacity to generate translation-ready insights, strengthening the pipeline from fundamental discovery to clinical understanding and care.

Impact Snapshot: AV-Funded Foundational Science to Date

 **55M+**

In follow-on funding secured by AV-supported investigators, reflecting strong external validation and sustained scientific momentum

 **210+**

Peer-reviewed publications advancing shared scientific knowledge and shaping the direction of the field

 **20+**

Biomarkers, risk factors, or therapeutic targets identified across projects, creating new entry points for mechanistic and translational research

SVRF: Building Depth and Driving Toward Outcomes

With 80+ awards granted and nearly **\$49M invested**, SVRF has supported foundational research focused on understanding the organ- and multi-organ-level mechanisms that drive long-term morbidity and mortality in single ventricle heart disease. SVRF’s portfolio shows a clear evolution toward outcomes-driven, clinically aligned science that reflects deepening biological insight and a maturing field.



When I was first exposed to single ventricle, we had an idea, a hypothesis, and a passion, but no track record in single ventricle, and no preliminary data. Traditional mechanisms wouldn’t have funded that research. SVRF let us pursue a promising novel hypothesis immediately, without wasting years overcoming the usual barriers.

— Jay Humphrey, PhD / SVRF 2021



One of the biggest challenges in single ventricle research is the lack of model systems that can predict patient risk and outcomes. This project is building a more physiologically relevant, human-based model of early heart development — with the goal of identifying biomarkers and pathways early enough to intervene, before surgical options become the only path forward.

— Kevin Costa, PhD / SVRF 2024

CSA: Accelerating Discovery through Team Science

With over **\$13M in funding** from Additional Ventures and the American Heart Association, CSA teams bring together expertise across genomics, imaging, developmental biology, and clinical cardiology — enabling discoveries that would not be possible within a single discipline or institution and catalyzing insights that emerge only when disciplines intersect.




Early intervention is critical for improving neurodevelopmental outcomes, but it’s not always accessible or timely. Our goal is to use genetics to identify risk at birth, so children with single ventricle heart disease can receive the support they need as early as possible — and CSA made that kind of collaborative, high-powered research possible.

— Casey Gifford, PhD / CSA 2024



Arrhythmias are one of the most serious and least predictable complications of single ventricle heart disease. CSA made it possible to combine patient-derived data, clinical-grade imaging, and computational modeling — along with the necessary collaborations — to begin understanding individual arrhythmia risk and explore noninvasive ways to test potential interventions safely.

— Stacey Rentschler, MD, PhD / CSA 2024



USC Photo/Chris Shinn

Ellis Meng, PhD

Through her SVRF project (“Non-Contact Flow Sensors for Pediatric Vascular Shunts”), Dr. Ellis Meng is leveraging advanced bioengineering to address one of the most fragile moments in single ventricle care.


For infants with single ventricle heart disease, surviving the first months of life often requires a small implanted shunt to stabilize blood flow between surgeries. While lifesaving, these shunts leave patients vulnerable to sudden and dangerous flow disturbances. Current devices offer minimal visibility once implanted, often leaving clinicians unable to respond until a child becomes critically ill.

Meng and her team are developing a contactless, implantable flow sensor designed to continuously monitor blood flow within the shunt. Working closely with surgeons and cardiologists, the team identified a sensing method that meets strict clinical requirements and performs within the critical flow range for this population. The team continues to test and iterate upon prototypes. If successful, this technology could enable earlier detection of complications, helping more infants safely reach their next surgery.



Once that tiny piece of tubing is implanted, it’s incredibly difficult to know what’s happening inside. Our goal is to detect changes early, before a child is sick enough to need an emergency room visit.”

Adult Heart with complex SVD



Andrew Cook, PhD

Through his SVRF project (“HiP-CTxSVD: Deep Phenotyping of Single Ventricle Disease”), Dr. Andrew Cook is building the anatomical foundation needed for more precise single ventricle care.

Single ventricle heart disease encompasses a number of diverse heart defects, yet treatment pathways are often applied uniformly. Cook is creating an open-source 3-D atlas of single ventricle anatomy to better understand this heterogeneity and inform more individualized treatment approaches.

Using Hierarchical Phase-Contrast Tomography (HiP-CT), a synchrotron-based imaging technique, his team can visualize preserved human hearts in 3-D at microscopic resolution — without destroying them. To date, they have reconstructed more than 120 fetal hearts across multiple single ventricle phenotypes and stages of life, forming an unprecedented digital repository for research and modeling.

Working through the European Research Collaborative of Cardiac Archives (EuReCCA) consortium, rare European archives are being digitized and preserved, creating a foundational resource to support future modeling, mechanism discovery, and more tailored intervention decisions.




It’s transformative. We’ve never been able to see and explore the heart in this way before. By rewriting our understanding of single ventricle heart disease structure — from whole organ to the molecular level — we can hope for a new dawn in single ventricle treatment.”

Translational Accelerator Launched: Creating Pathways from Concept to Clinic

The launch of Additional Ventures' first-in-field Translational Accelerator marks a pivotal moment for single ventricle research. The Translational Accelerator is intentionally designed to address one of the field's most persistent bottlenecks: the gap between early discovery and real-world application.

Through milestone-based funding, hands-on development support, and strategic partnerships, the Accelerator equips innovators to overcome early barriers in a field where no devices or therapeutics are purpose-built for single ventricle patients.



Since its origins, Additional Ventures has been visionary and innovative, unafraid to pursue novel approaches to tackling the devastating disease of single ventricle syndrome. The Translational Accelerator is yet another example of this. Organizations like the NIH are well-suited to supporting early-stage, basic innovation, and device companies excel at commercializing great ideas — but there is often a chasm between those two stages. The Accelerator is uniquely positioned to bridge that gap.”



Anthony Philippakis, MD, PhD
Partner, Google Ventures (GV)

Launching a New Pathway for Device Innovation

In its inaugural year, AV launched the first program under the Translational Accelerator: the **Device Innovation Award**. This award targets early-stage devices engineered specifically for single ventricle physiology, addressing a critical unmet need in a population reliant on adapted tools never designed with them in mind.

Together, these elements mark a natural progression and strategic expansion of AV's approach that builds on and complements our foundational investments in understanding single ventricle physiology with targeted support for technologies designed to translate insight into real-world impact.

The Device Innovation Award provides:



A focus on technologies that improve Fontan circulation, reduce physiologic burden, and address key sequelae such as lymphatic congestion, liver fibrosis, and exercise intolerance



Up to \$1M over three years in milestone-based funding, plus \$500K in in-kind services



Dedicated engineering, regulatory, and development support from a diverse network of organizations, including the **Consortium for Technology & Innovation in Pediatrics (CTIP)** and other strategic partners

What's Next: Expanding to Therapeutics

To build a parallel pathway for therapeutic development, Additional Ventures is finalizing a collaboration to launch a **Therapeutics Award** under the Translational Accelerator, providing clinical, regulatory, and commercialization expertise to help develop promising drug discoveries for single ventricle patients.

Cures Collaborative: Engineering the Missing Ventricle

While life-saving, the Fontan surgical pathway is a compromise that requires a lifetime of specialized care and exposes patients to progressive, multi-organ complications. The Additional Ventures Cures Collaborative (AVCC) was created to confront the core challenge of single ventricle heart disease by uniting a multidisciplinary, multi-institutional team around an unprecedented mission: replacing the missing pump.



AVCC 1.0: Establishing Feasibility of a Bioengineered, Pulsatile Conduit

In just five years, AVCC 1.0 has built the collaborative scientific and technical infrastructure required to realize this mission. Together, these key advances demonstrate scientific feasibility of replacing the missing ventricle and establish for the first time the tools, models, and collaborative infrastructure needed to pursue replicability and scale with rigor:



First durable large-animal model of Fontan physiology (“the Fontan lamb”) — enabling sustained study of long-term hemodynamics and end-organ failure



Functional bioengineered cardiac conduits — implanted in vivo, viable for 6-12 months, vascularized, and capable of generating measurable pulsatile pressure



Biomanufacturing at scale — reliable production of billions of cardiomyocytes and supporting cell types, with emerging strategies to mature them into functional myocardium



Model-guided design — multiphysics computational modeling now informs conduit geometry, placement, and performance, reducing trial-and-error and accelerating iteration

Ahead to AVCC 2.0: Advancing Function and Readiness

With feasibility established, AVCC 2.0 represents a deliberate shift from proving what's possible to building what's necessary by advancing functional complexity, strengthening reproducibility, and integrating biological, engineering, and manufacturing systems into a cohesive, scalable platform. In doing so, AVCC 2.0 moves the field toward a disciplined, system-level approach that ultimately makes replacement of the missing ventricle achievable.

Funding Breakthroughs in Single Ventricle Research


At Additional Ventures, our mission to cure single ventricle heart disease is realized through deliberate, strategic support across the full spectrum of research — advancing understanding of origins, improving outcomes, strengthening care, and pursuing curative solutions in parallel. Five years into this work, our funding approach continues to reflect that strategy, as well as the momentum building across the field.

Rather than advancing isolated projects, we have built a connected research ecosystem in which data

infrastructure, investigator communities, translational pathways, and clinical efforts reinforce one another. This integrated approach strengthens the field's capacity not only to generate new knowledge, but to rapidly translate that knowledge into meaningful improvements in care.

What has emerged is a research landscape that is more coordinated, more capable, and increasingly positioned to accelerate progress toward lasting solutions for people living with single ventricle heart disease.

Since our founding in 2020, we have committed **\$111.5 million — and counting — to advance single ventricle science and care.**




Strategically Investing to Advance Purpose-Built Single Ventricle Solutions

The pediatric device landscape is constrained by commercialization barriers that prevent many solutions from reaching patients. Below are two of Additional Ventures' strategic investments that accelerate technologies designed specifically for children with complex and life-threatening heart disease where adapted adult tools are no longer enough.

Corvion: Reimagining Mechanical Support for Pediatric Heart Failure

Corvion is addressing one of the most urgent gaps in pediatric heart failure care: the absence of durable, purpose-built mechanical circulatory support options for children. The company is redefining what's possible by developing a next-generation ventricular assist device (VAD) engineered specifically for children with advanced heart failure.

Built on the company's ultra-efficient adult platform, the pediatric VAD has demonstrated strong safety and performance in early preclinical studies and is advancing with support from NIH and Additional Ventures. Through our investment, Additional Ventures is building a new standard of care for children facing end-stage heart failure.



Starlight Cardiovascular: Bringing a Neonatal Ductus Arteriosus Stent to Clinic

Currently, there is no FDA-approved ductus arteriosus (DA) stent in the US, forcing clinicians to rely on repurposed adult devices or high-risk surgical shunts for critically ill newborns. Starlight Cardiovascular is working to change that reality.

This year, the FDA granted an Investigational Device Exemption (IDE) for Starlight's Lifeline™ DA Stent System, enabling a multi-center clinical study of a purpose-built stent designed specifically for neonates. With Additional Ventures' support, this first-in-class device is moving closer to the clinic — reducing reliance on adapted adult technologies and aiming to improve survival and early-life outcomes for babies born with the most complex forms of congenital heart disease.



Join Us at **SVIM 2026** to Advance Discovery and Collaboration across Single Ventricle

From **October 7 to 9, 2026**, the Single Ventricle Investigator Meeting — our industry-leading, multidisciplinary convening focused exclusively on accelerating progress in single ventricle heart disease — returns.

SVIM welcomes professionals from across the single ventricle research spectrum to gather in Denver, CO, learn and share novel developments, and spark collaborative opportunities that strengthen and accelerate our mission to cure single ventricle.

No matter how your work relates to revolutionizing treatment and care in single ventricle heart disease, you belong here.



“
There are experts from so many different fields. It’s not all engineers. It’s not all clinicians. It’s bringing everybody together and saying, how can we work as a team to solve these challenging, important problems?”

 **Jay Humphrey, PhD**

**SVIM
2026**



Oct 7-9 | Denver, CO

SVIM invites:



Early-career and established researchers



Basic and translational scientists



Clinicians



Engineers



Data scientists

Letter from the CEO

As we look back on 2025, one thing is increasingly clear: progress in single ventricle heart disease is no longer limited by the absence of good ideas. It is shaped by whether those ideas are supported by the right structures, pathways, and partnerships to move from insight to impact.

Over the past year, Additional Ventures has focused on building those conditions with intention. SOURCE continued to grow as shared infrastructure for discovery, pairing genomic scale with clinical depth and broad participation from patients and families. Our Foundational Science programs strengthened the field by investing in investigators and teams capable of asking more integrated, outcome-oriented questions. The launch of the Translational Accelerator addressed a long-standing gap between discovery and application, creating clear pathways for promising technologies to advance. And through the Cures Collaborative and targeted strategic investments, we continued to work across time horizons, pursuing transformative long-term solutions while also addressing urgent unmet needs facing patients today.

Taken together, this work reflects a deliberate approach: not a collection of programs, but an intentionally designed, end-to-end innovation engine. Each component reinforces the others: shared data informs discovery, discovery feeds translation, translation enables intervention, and long-horizon efforts are supported by platforms built for rigor and scale. This integrated perspective is reflected in our 2026 Research Roadmap, which emphasizes outcomes, readiness, and connection over isolated milestones.

Looking ahead, our focus remains on strengthening the links between these efforts. In the years to come, we will continue to expand access to shared resources, support the development of purpose-built solutions for single ventricle patients, and invest where existing systems fall short scientifically, commercially, or clinically. We will deepen our commitment to approaches that can move in parallel rather than in sequence, recognizing that meaningful progress requires coordinated advances across disciplines and timeframes.

The progress captured in this report is the result of a growing community of patients, families, investigators, clinicians, partners, and supporters that are working together within a system designed for impact. We are deeply grateful for that collective effort and shared resolve.

As we move forward, we do so with a deep commitment to build on what we have established and accelerate toward outcomes that truly change what is possible for people living with single ventricle heart disease.

With gratitude,



Kirstie Keller, PhD
CEO

Additional Ventures Team

Erin Hoffmann
Executive Chairman & Founder

Dylan Barbera, PhD
Program Officer

Megan N. Freeland, PharmD
Director of Communications

Diane Pickles
Director of SOURCE

Mike Schroepfer
Founder

Kaitlin Davis, PhD
Director of Translational Science

Taylor MacLean
Program Manager

Stefânia Forner
Director of Foundational Sciences

Kirstie Keller, PhD
CEO

Ashley Ford
Executive Assistant

Tiana Medley, PhD, PMP
Program Officer

Courtney Steger, PhD
Program Manager

Scientific Advisory Board

Deepak Srivastava, MD
President, Gladstone Institutes
Professor, University of California,
San Francisco

Daniel Licht, MD
Professor of Neurology
Children's National Hospital

R. Mark Payne, MD
Professor of Pediatrics
Professor of Medical & Molecular
Genetics, Indiana University School
of Medicine

Cecilia Lo, PhD, FAHA
Distinguished Professor and
F. Sargent Cheever Chair in
Developmental Biology
University of Pittsburgh

Anthony Philippakis, MD, PhD
General Partner
Google Ventures

Alison Marsden, PhD
Professor of Pediatrics -
Cardiology and Bioengineering
Stanford University

Anthony B. Firulli, PhD
Endowed Professor of Pediatrics
Indiana University School of
Medicine

Shelley Miyamoto, MD
Jack Cooper Millison Chair
in Pediatric Heart Disease
Professor of Pediatrics
Director, Cardiomyopathy Program
University of Colorado and
Children's Hospital Colorado

Rahul Rathod, MD, MBA
Associate Cardiologist-in-Chief at Boston Children's Hospital
Associate Professor at Harvard Medical School
Director of the Single Ventricle Program and the Fontan Clinic
at Boston Clinic at Boston Children's Hospital

Mark Skylar Scott, PhD
Assistant Professor
of Bioengineering
Stanford University

Patient & Family Advisory Board

Tawanna Williams, CPC
Mother to a Post-Heart Transplant
Single Ventricle Daughter
Patient Advocacy and Health
Equity Manager

Bulent Arman Aksoy, PhD
Computational Biologist
Father to a Single Ventricle
Daughter

Taylor Houlihan, MD
Pediatric Resident
Single Ventricle Fontan Patient

Jameson Rich
Writer and Filmmaker
Post-Fontan Single Ventricle,
Bi-ventricular Repair

Carolyn Ruocco
Writer and learning designer;
Mother to 2 boys, one with Single
Ventricle

Stacey Lihn
Paralegal; Mother to a Single
Ventricle daughter

Scott Leezer
Public Affairs Consultant,
CHD Policy & Advocacy Leader;
Single Ventricle Patient

ADDITIONAL
VENTURES